Eleven Therapeutics

Eleven Therapeutics ushers in the next generation of RNAi therapies by integrating artificial intelligence (AI), large-scale parallel functional assays, and combinatorial chemistry. Its flagship innovation features a novel modality called SCSI-RNA™ (Single Chassis, Small interfering RNA), a fully programmable molecule rationally designed to address delivery, durability, and efficacy challenges for any disease or biological target of interest. Founded in 2020 by a group of globally leading interdisciplinary scientists, Eleven Therapeutics leverages its world-class talent pool through three collaborative hubs based in Cambridge, UK, to bring novel RNAi therapies to patients in need. Eleven is currently focusing its development pipeline on siRNA treatments for a range of respiratory diseases.